#United States #New York #Class Action #Faruqi & Faruqi #INOVIO Pharmaceuticals

Inovio Pharmaceuticals Shareholders Alert

Faruqi & Faruqi, LLP, a nationally recognized law firm specializing in securities litigation, is urging Inovio Pharmaceuticals investors to pay close attention to an important deadline regarding a class action lawsuit. The firm has raised the alarm for those who purchased or acquired Inovio's securities between October 10, 2023, and December 26, 2025. Investors must act by April 7, 2026, if they wish to lead the case and assert their rights.

Overview of Allegations

Faruqi & Faruqi has embarked on investigating potential claims against Inovio Pharmaceuticals, Inc., which is publicly traded under the NASDAQ symbol INO. The allegations revolve around serious infringements of federal securities laws. The company is accused of misleading investors regarding production issues with the CELLECTRA device, which they claimed would impact regulatory submissions involving the INO-3107 BLA (Biologics License Application).

Specifically, the lawsuit alleges that:
1. Manufacturing deficiencies regarding Inovio’s CELLECTRA device had been concealed from investors.
2. Consequently, the company was unlikely to submit the INO-3107 BLA for regulatory approval by the previously communicated timeline.
3. Inovio failed to obtain sufficient evidence to validate claims for accelerated approval from the FDA.
4. The overall prospects for regulatory approval and market success for the INO-3107 treatment were overstated.
5. Public statements made by the company were materially false and misleading at all relevant times.

These claims came to the forefront following a significant announcement by the FDA on December 29, 2025, which clarified the status of Inovio's BLA. The regulatory body accepted the application for INO-3107; however, it noted that Inovio did not provide adequate justification for pursuing accelerated approval—contradicting what had been suggested to investors. Following this news, Inovio's stock took a major hit, plummeting to a near 25% drop in value in a single trading day.

What This Means for Investors

For investors affected by these developments, the importance of the April 7 deadline cannot be overstated. The lead plaintiff serves a pivotal role by overseeing the lawsuit on behalf of the class and may influence the proceedings significantly. Any affected individual is encouraged to consult legal counsel to determine their eligibility to serve as lead plaintiff or to participate in the class action suit.

This news serves as a reminder of the volatility and risks associated with investing in biotechnology companies that are reliant on successful regulatory pathways for their products. In light of these allegations, potential investors should also exercise caution, conducting thorough due diligence before making investment decisions.

How to Get Involved

Individuals who believe they qualify as members of the class can learn more about their rights by visiting Faruqi & Faruqi's website. They may also contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 to discuss their options for involvement in the class action.

Furthermore, the firm invites anyone with additional insights related to Inovio's business practices to come forward, including whistleblowers and former employees. The opportunity to participate in this class action underscores the critical importance of investor advocacy in the face of misleading company practices.

Conclusion

With significant implications for involved investors, the Inovio Pharmaceuticals case exemplifies the ongoing need for vigilance in monitoring legal proceedings impacting shareholder rights. As the April 2026 deadline approaches, stakeholders are urged to act and seek advice to protect their interests effectively.